Navigation Links
IsoTis Adjourns Special Meeting to October 26, 2007
Date:10/24/2007

s stockholders a definitive proxy statement and other relevant documents in connection with the special stockholder meeting for the proposed transaction. IsoTis stockholders are urged to read the definitive proxy statement and other relevant materials when they become available because they will contain important information about IsoTis, Integra and the proposed transaction. Investors may obtain a free copy of these materials and other documents filed by IsoTis with the Securities and Exchange Commission at the SEC's website at http://www.sec.gov, at IsoTis' website at http://www.isotis.com or by sending a written request to IsoTis at 2 Goodyear, Irvine, California 92618, Attention: Chief Financial Officer.

IsoTis and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in favor of the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of IsoTis' stockholders in connection with the proposed transaction will be set forth in IsoTis' revised definitive proxy statement for its special meeting. Additional information regarding these individuals and any interest they have in the proposed transaction is set forth in the revised definitive proxy statement when it is filed with the SEC.


'/>"/>
SOURCE IsoTis Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Calcium Plus Assay Kit, Superior Detection for Specialized Targets
2. Neurognostics receives special FDA clearance for MindState fDAD
3. Berbee designated a Microsoft Small Business Specialist
4. Special needs addressed at Web Usability Conference
5. OASYS Online Provides Special Education Data Management
6. AG accuses BioCATT of violating meetings law
7. VC trends, company progress discussed at Mason Wells portfolio meeting
8. Beware the Dreaded Off-Site Technology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SAN DIEGO , Aug. 31, 2015 ... drug development company announces that the Company,s lead antibody, ... subject of five separate presentations during the upcoming World ... Hawaii September 2-5, 2015. Researchers from the ... (MSK) will present results on the use of MabVax,s ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... 2015 FLX Bio, Inc., a biopharmaceutical company ... immunotherapies, announced today that it has appointed Brian ... William Ho , M.D., Ph.D., as Chief Medical ... team led by veterans of Flexus Biosciences, Inc., FLX,s ... Officer; Jay Powers , Ph.D., Vice President, Drug ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment ... is the first commercially available new FDA approved system in the last 14 years, ... 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... ... new partner and sponsor in Life Line Screening. The two companies aim to ... abdominal aortic aneurysm and , peripheral arterial disease screening . Life Line ... its customers can easily donate money to the foundation. , ...
... , SAN DIEGO, Dec. 9 ... top-line efficacy and safety results from the Tulip PETAL Study ... proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in ... data from the Tulip PETAL Study are consistent with what ...
... , Nashville, Tenn., Dec. 9 Cumberland Pharmaceuticals ... entered into an exclusive agreement with DB Pharm Korea Co. ... ( ibuprofen ) Injection in South Korea. Designed to treat pain ... U.S. Food and Drug Administration and launched by Cumberland in the ...
Cached Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... Studies show the incidence of diabetes in dogs has increased ... Missouri veterinarians have changed the way veterinarians treat diabetes in ... humans. Dogs are susceptible to type 1, insulin-dependent diabetes. ... because their bodies do not produce enough insulin, a hormone ...
... around the world have forced many species to the brink ... multiple causes that are still not fully understood, researchers conclude ... causative factor is often missing the larger picture, they said, ... don,t consider the totality of causes or could even ...
... April 25, 2011 - Call them the Jason Bournes of ... secret agents, some bacteria avoid antibiotic treatments by essentially shutting ... says Thomas Wood, professor in the Artie McFerrin Department of ... elaborate survival mechanism is explained in the online April edition ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Catastrophic amphibian declines have multiple causes, no simple solution 2Catastrophic amphibian declines have multiple causes, no simple solution 3'Going off the grid' helps some bacteria hide from antibiotics 2'Going off the grid' helps some bacteria hide from antibiotics 3